Rims1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RIMS1 (Regulating Synaptic Membrane Exocytosis Protein 1), also known as RIM1α, is a 1858-amino acid presynaptic active zone protein that regulates synaptic vesicle priming, docking, and Ca²⁺-triggered release.
| Attribute |
Value |
| Protein Name |
RIMS1 (RIM1α) |
| Gene |
RIMS1 |
| UniProt ID |
Q86YW5 |
| Molecular Weight |
206 kDa |
| Subcellular Localization |
Presynaptic active zone |
| Protein Family |
RIM family (RIM1, RIM2, RIM3, RIM4) |
RIMS1 contains multiple domains:
- N-terminal PDZ domain: Scaffolds to presynaptic density
- Zinc finger domain: Rab3 binding
- C2A domain: Ca²⁺/phospholipid binding
- C2B domain: Protein interactions
- C-terminal proline-rich region: Interactions with other proteins
RIMS1 is essential for synaptic transmission:
- Vesicle Priming: Facilitates synaptic vesicle priming
- Ca²⁺ Channel Coupling: Couples voltage-gated Ca²⁺ channels to vesicles
- Rab3 Interaction: Binds Rab3/Rab27 to regulate vesicle cycling
- Active Zone Scaffold: Organizes active zone proteins
- Release Regulation: Modulates release probability and kinetics
- Altered active zone function affects synaptic transmission
- RIMS1 may be involved in synaptic loss
- RIM dysfunction affects dopaminergic vesicle release
- May contribute to neurodegeneration
- Dominant mutations cause epileptic encephalopathy
- Affects release probability and causes seizures
- Mutations cause inherited retinal degeneration
- RIMS1 essential for photoreceptor function
| Approach |
Target |
Status |
| Small molecule modulators |
RIMS1-Ca²⁺ channel coupling |
Research |
| Gene therapy |
AAV-RIMS1 for retinal degeneration |
Preclinical |
- RIM function in synaptic transmission - Nat Neurosci (2005) - PMID:15838578
- RIM structure - Neuron (2006) - PMID:17018285
- RIMS1 mutations in cone-rod dystrophy - Nat Genet (2010) - PMID:20485450
- Active zone organization - Neuron (2017) - PMID:28712652
The study of Rims1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Wang SS, et al. (2016). 'RIM-binding proteins in synaptic transmission.' Physiological Reviews. PMID:27440251
- Deng L, et al. (2011). 'RIM proteins and Ca2+ channel functions in synaptic transmission.' Cell Calcium. PMID:21349627
- Acuna C, et al. (2016). 'RIM-BP2 controls presynaptic Ca2+ channel nanodocks.' Cell. PMID:27545350
- Kaeser PS, et al. (2011). 'RIM proteins and synaptic vesicle priming.' Neuron. PMID:21962581
- Han Y, et al. (2011). 'RIM controls synaptic vesicle priming.' Nature. PMID:21962582
- Koch H, et al. (2020). 'RIM-binding proteins in synaptic ribbon functions.' Cell Calcium. PMID:31972542
- Zhou P, et al. (2019). 'RIM and synaptic vesicle cycling.' Neuroscience. PMID:30625632
- Moser T, et al. (2020). 'RIM in auditory ribbon synapses.' Hearing Research. PMID: 320 Chubber
RIMS1 has been implicated in several neurodegenerative and neurological conditions:
- Alzheimer's Disease: RIMS1 expression is altered in AD brains, affecting synaptic vesicle cycling and contributing to synaptic dysfunction. Studies show reduced RIMS1 levels in hippocampal synapses of AD patients.
- Parkinson's Disease: Dysregulation of RIMS1 may contribute to dopaminergic synaptic vesicle deficits in PD. The protein interacts with alpha-synuclein in presynaptic terminals.
- Epilepsy: RIMS1 mutations are associated with epileptic encephalopathy, highlighting its critical role in synaptic transmission.
- Intellectual Disability: Rare de novo variants in RIMS1 have been identified in patients with intellectual disability and autism spectrum disorders.
RIMS1 represents a potential therapeutic target for synaptic disorders:
- Synaptic Plasticity Enhancers: Compounds that enhance RIMS1 function may improve synaptic vesicle replenishment in neurodegenerative diseases.
- Gene Therapy Approaches: AAV-mediated RIMS1 delivery is being explored for synaptic failure in AD and PD.
- Small Molecule Modulators: Pharmacological modulation of RIM-RAB3 interactions could enhance neurotransmitter release.
Current research focuses on:
- Understanding the structure-function relationships of RIM1α domains
- Developing RIM1α-targeted therapeutics for synaptic disorders
- Investigating RIMS1 interactions with other active zone proteins
- Exploring RIM-binding protein 2 (RIM-BP2) interactions
- RIMS1 Knockout Mice: Show embryonic lethality, indicating essential role in development.
- Conditional KO Models: Synapse-specific deletion reveals deficits in synaptic vesicle priming and Ca²⁺-triggered release.
- Transgenic Models: Overexpression studies demonstrate enhanced synaptic plasticity.